表观基因组启动子改变预测转移性胃癌免疫检查点抑制的获益
该研究分析两个转移性胃癌免疫治疗队列,采用NanoString平台和RNAseq检测替代启动子利用率。高水平替代启动子利用(APhigh)肿瘤T细胞胞解活性标志物降低,客观缓解率8%对42%(P=0.03),中位无进展生存期55天对180天(P=0.0076)。多因素分析中替代启动子利用是免疫治疗生存的独立预测因子(HR 0.29,95%CI 0.099-0.85,P=0.024)。
要点
- 替代启动子高水平利用(APhigh)与转移性胃癌免疫检查点抑制原发耐药相关。
- APhigh组客观缓解率8%对42%(P=0.03),中位无进展生存期55天对180天(P=0.0076)。
- 替代启动子利用是免疫治疗生存的独立预测因子(HR 0.29,95%CI 0.099-0.85,P=0.024)。
核心结论
- 相当比例的转移性胃癌通过替代启动子利用实现免疫逃逸,这些肿瘤可能对anti-PD1免疫检查点抑制耐药。
- 替代启动子利用是免疫检查点抑制耐药的潜在机制,也是免疫治疗的新型预测生物标志物。
研究设计与样本
- 分析两个接受免疫治疗的转移性胃癌患者队列。
- 第一队列N=24,接受纳武利尤单抗或帕博利珠单抗治疗,用NanoString平台在存档组织样本检测替代启动子利用。
- 第二队列为一项II期临床试验,N=37,统一接受帕博利珠单抗治疗,获取新鲜肿瘤活检,对RNAseq数据进行转录组分析。
- 试验注册号:ClinicalTrials.gov NCT#02589496。
主要发现
- 第一队列24例中8例(33%)为高替代启动子利用(APhigh),以此定义第二队列APhigh三分位(37例中13例APhigh)。
- APhigh肿瘤T细胞胞解活性标志物降低,缓解率较低(8%对42%,P=0.03)。
- APhigh组中位无进展生存期较低(55天对180天,P=0.0076)。
- 多因素分析中替代启动子利用是免疫治疗生存的独立预测因子(HR 0.29,95%CI 0.099-0.85,P=0.024)。
- 通过配对治疗前和治疗后活检分析肿瘤演变,观察到与临床缓解相关的替代启动子利用率一致性变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Utilization of alternative transcription start sites through alterations in epigenetic promoter regions causes reduced expression of immunogenic N-terminal peptides, which may facilitate immune evasion in early gastric cancer. We hypothesized that tumors with high alternate promoter utilization would be resistant to immune checkpoint inhibition in metastatic gastric cancer. PATIENTS AND METHODS: Two cohorts of patients with metastatic gastric cancer treated with immunotherapy were analyzed. The first cohort (N = 24) included patients treated with either nivolumab or pembrolizumab. Alternate promoter utilization was measured using the NanoString® (NanoString Technologies, Seattle, WA, USA) platform on archival tissue samples. The second cohort was a phase II clinical trial of patients uniformly treated with pembrolizumab (N = 37). Fresh tumor biopsies were obtained, and transcriptomic analysis was carried out on RNAseq data. Alternate promoter utilization was correlated to T-cell cytolytic activity, objective response rate and survival. RESULTS: In the first cohort 8 of 24 (33%) tumors were identified to have high alternate promoter utilization (APhigh), and this was used to define the APhigh tertile of the second cohort (13 APhigh of 37). APhigh tumors exhibited decreased markers of T-cell cytolytic activity and lower response rates (8% versus 42%, P = 0.03). Median progression-free survival was lower in the APhigh group (55 versus 180 days, P = 0.0076). In multivariate analysis, alternative promoter utilization was an independent predictor of immunotherapy survival [hazard ratio 0.29, 95% confidence interval 0.099-0.85, P = 0.024). Analyzing tumoral evolution through paired pre-treatment and post-treatment biopsies, we observed consistent shifts in alternative promoter utilization rate associated with clinical response. CONCLUSION: A substantial proportion of metastatic gastric cancers utilize alternate promoters as a mechanism of immune evasion, and these tumors may be resistant to anti-PD1 immune checkpoint inhibition. Alternate promoter utilization is thus a potential mechanism of resistance to immune checkpoint inhibition, and a novel predictive biomarker for immunotherapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT#02589496.
引用
- Sundar R, Huang KK, Qamra A, et al. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Ann Oncol. 2019. PMID: 30624548. doi:10.1093/annonc/mdy550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。